- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00651183
Non-motor Symptoms (Depressive Symptoms) of Parkinson's Disease and Their Course Under Pramipexole Treatment
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Amstetten, Austria
- Boehringer Ingelheim Investigational Site
-
Bad Hall, Austria
- Boehringer Ingelheim Investigational Site
-
Bad Ischl, Austria
- Boehringer Ingelheim Investigational Site
-
Bad Radkersburg, Austria
- Boehringer Ingelheim Investigational Site
-
Baden, Austria
- Boehringer Ingelheim Investigational Site
-
Bregenz, Austria
- Boehringer Ingelheim Investigational Site
-
Bruck an der Mur, Austria
- Boehringer Ingelheim Investigational Site
-
Deutschlandsberg, Austria
- Boehringer Ingelheim Investigational Site
-
Dornbirn, Austria
- Boehringer Ingelheim Investigational Site
-
Eisenstadt, Austria
- Boehringer Ingelheim Investigational Site
-
Feldkirch, Austria
- Boehringer Ingelheim Investigational Site
-
Feldkirchen, Austria
- Boehringer Ingelheim Investigational Site
-
Gmunden, Austria
- Boehringer Ingelheim Investigational Site
-
Graz, Austria
- Boehringer Ingelheim Investigational Site
-
Grieskirchen, Austria
- Boehringer Ingelheim Investigational Site
-
Gänserndorf, Austria
- Boehringer Ingelheim Investigational Site
-
Hall in Tirol, Austria
- Boehringer Ingelheim Investigational Site
-
Hallein, Austria
- Boehringer Ingelheim Investigational Site
-
Hermagor, Austria
- Boehringer Ingelheim Investigational Site
-
Hohenems, Austria
- Boehringer Ingelheim Investigational Site
-
Hollabrunn, Austria
- Boehringer Ingelheim Investigational Site
-
Horn, Austria
- Boehringer Ingelheim Investigational Site
-
Imst, Austria
- Boehringer Ingelheim Investigational Site
-
Innsbruck, Austria
- Boehringer Ingelheim Investigational Site
-
Judenburg, Austria
- Boehringer Ingelheim Investigational Site
-
Kapfenberg, Austria
- Boehringer Ingelheim Investigational Site
-
Klagenfurt, Austria
- Boehringer Ingelheim Investigational Site
-
Klosterneuburg, Austria
- Boehringer Ingelheim Investigational Site
-
Knittelfeld, Austria
- Boehringer Ingelheim Investigational Site
-
Krems, Austria
- Boehringer Ingelheim Investigational Site
-
Kufstein, Austria
- Boehringer Ingelheim Investigational Site
-
Leoben, Austria
- Boehringer Ingelheim Investigational Site
-
Lienz, Austria
- Boehringer Ingelheim Investigational Site
-
Lilienfeld, Austria
- Boehringer Ingelheim Investigational Site
-
Linz, Austria
- Boehringer Ingelheim Investigational Site
-
Melk, Austria
- Boehringer Ingelheim Investigational Site
-
Neunkirchen, Austria
- Boehringer Ingelheim Investigational Site
-
Oberwart, Austria
- Boehringer Ingelheim Investigational Site
-
Ried im Innkreis, Austria
- Boehringer Ingelheim Investigational Site
-
Salzburg, Austria
- Boehringer Ingelheim Investigational Site
-
Scheibbs, Austria
- Boehringer Ingelheim Investigational Site
-
Schwechat, Austria
- Boehringer Ingelheim Investigational Site
-
Spital an der Drau, Austria
- Boehringer Ingelheim Investigational Site
-
St. Johann im Pongau, Austria
- Boehringer Ingelheim Investigational Site
-
St. Pölten, Austria
- Boehringer Ingelheim Investigational Site
-
St. Veit an der Glan, Austria
- Boehringer Ingelheim Investigational Site
-
Stegersbach, Austria
- Boehringer Ingelheim Investigational Site
-
Stockerau, Austria
- Boehringer Ingelheim Investigational Site
-
Telfs, Austria
- Boehringer Ingelheim Investigational Site
-
Traun, Austria
- Boehringer Ingelheim Investigational Site
-
Villach, Austria
- Boehringer Ingelheim Investigational Site
-
Vöcklabruck, Austria
- Boehringer Ingelheim Investigational Site
-
W. Neustadt, Austria
- Boehringer Ingelheim Investigational Site
-
Wels, Austria
- Boehringer Ingelheim Investigational Site
-
Wien, Austria
- Boehringer Ingelheim Investigational Site
-
Wolfsberg, Austria
- Boehringer Ingelheim Investigational Site
-
Wörgl, Austria
- Boehringer Ingelheim Investigational Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Idiopathic PD with or without fluctuations
- Indication for treatment with Pramipexole
- Presence of at least mild depressive symptoms (as judged by the treating physician)
- Ability to reliably complete a self-rating scale (Hospital Anxiety and Depression Scale (HADS))
Exclusion Criteria:
- Any contraindications according to the Summary of Product Characteristics (SPC), hypersensitivity to pramipexole or to any of the excipients
- Ongoing treatment with pramipexole
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I (Mentation, Behaviour and Mood)
Lasso di tempo: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Rating scale scored from 0 (none) - 4 (severe). The UPDRS Part I (Mentation, Behaviour and Mood during the Past Week) consist of 4 items, each of them is scored from 0 (normal) to 4 (severe). Reduction in this score over time is interpreted as improvement. Total UPDRS part I score ranges from 0 = best score to 16 = worst score |
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
|
Change From Baseline in Hospital Anxiety and Depression Scale - HADS-D Depression Subscore
Lasso di tempo: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Depression Scale - 7 items scored for each individual question from 0 = best and 3 = worst. HADS is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises of 14 items, thereof seven statements describe anxiety and seven statements depression. Each answer is rated on a four-point scale (0-3). All seven answers are summarized and calculated to a total score to the anxiety scale and to the depression scale with a maximum score of 21 points for each scale. |
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
|
Change From Baseline in Hospital Anxiety and Depression Scale - HADS-A Anxiety Subscore
Lasso di tempo: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Anxiety Scale - 7 items scored for each individual question from 0 = best and 3 = worst. HADS is a self-assessment scale for the symptom severity of anxiety disorders and depression. It comprises of 14 items, thereof seven statements describe anxiety and seven statements depression. Each answer is rated on a four-point scale (0-3). All seven answers are summarized and calculated to a total score to the anxiety scale and to the depression scale with a maximum score of 21 points for each scale. |
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
|
Change From Baseline in UPDRS Part III (Motor Examination)
Lasso di tempo: Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
14 components rating scale with 27 items scored by 0 (none) - 4 (severe)
|
Baseline and Final (visit 3) - Change from baseline (i.e. decrease of score)
|
Collaboratori e investigatori
Sponsor
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Sintomi comportamentali
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie parkinsoniane
- Malattie dei gangli basali
- Disturbi del movimento
- Sinucleinopatie
- Malattie Neurodegenerative
- Depressione
- Morbo di Parkinson
- Effetti fisiologici delle droghe
- Agenti neurotrasmettitori
- Meccanismi molecolari dell'azione farmacologica
- Agenti protettivi
- Agonisti della dopamina
- Agenti dopaminergici
- Antiossidanti
- Agenti antiparkinson
- Agenti anti-discinesia
- Pramipexolo
Altri numeri di identificazione dello studio
- 248.649
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .